Evidence map›Paper›PMID 36156264›Full record

ArticleTransfusion2022

When should RhD-negative recipients be spared the transfusion of DEL red cells to avoid anti-D alloimmunization?

Hitoshi Ohto, Willy Albert Flegel, Hana Safic Stanic

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Two Cases of Anti-D Alloimmunization in D-Negative Thai Patients as a Result of the Asian-Type DEL on Transfused Red Cells.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Hitoshi OhtoDepartments of Mesenchymal Stem Cell Research, Blood Transfusion and Transplantation Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan.ORCID 0000-0003-0340-883X
Willy Albert FlegelDepartment of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-1631-7198
Hana Safic StanicDepartment of Immunohematology, Croatian Institute of Transfusion Medicine, Zagreb, Croatia.ORCID 0000-0001-8981-9247
Croatian Institute of Transfusion Medicine · HRFukushima Medical University · JPNational Institutes of Health Clinical Center · US

Funding

Laboratory Services Section, Department of Transfusion Medicine Core ReportZICCL002128 · CLC · CLINICAL CENTER · PI FLEGEL, WILLY · 2020 to 2025
$0k
Intramural NIH HHS ZIC CL002128NIH HHS Project ZIC CL002128
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Rh-Hr Blood-Group SystemRho(D) Immune GlobulinBlood TransfusionHumansIsoantibodiesIsoantibodiesRh-Hr Blood-Group SystemRHO(D) antibodyRho(D) Immune Globulinalloimmunizationanti-DDELmolecular typingred cell genotyping

Identifiers

PMID36156264
PMCPMC9643616
OpenAlexW4297237007

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.